Abstract
Background Chronic obstructive pulmonary disease (COPD) is the third leading cause of global mortality. Emerging evidence suggests the oral microbiome may contribute to COPD progression, though causal relationships remain elusive.
Methods Using bidirectional Mendelian randomization (MR) on East Asian genome-wide association study (GWAS) summary data, we assessed causal links between oral microbial taxa and COPD risk. Subsequently, hub genes in COPD bulk RNA sequencing data were identified by integrating the Protein-Protein Interaction (PPI) network with logistic regression, followed by target validation using single-cell RNA sequencing, immune infiltration analysis, and molecular docking.
Results Forward MR identified 48 taxa associated with COPD, primarily from genera such as Fusobacterium, Prevotella, and Streptococcus. Reverse MR detected 79 taxa affected by COPD, mainly involving Campylobacter, Rothia, and Streptococcus. Through the PPI network, logistic regression screening, and multi-omics analysis validation, MPDZ emerged as a key hub gene, upregulated in Ciliated cells and linked to immune dysregulation. Molecular docking revealed six candidate drugs with strong binding affinity to MPDZ.
Conclusion Our study identified bidirectional causal associations between the oral microbiota and COPD in East Asian populations and prioritized candidate targets relevant to COPD pathogenesis, potentially offering new insights for future mechanistic studies and therapeutic exploration.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://ftp2.cngb.org/pub/CNSA/data5/CNP0001664/ https://opengwas.io/datasets/bbj-a-103 https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90018001-GCST90019000/GCST90018587/ https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57148 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE173896
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Co-first author
We have made three revisions in response to the reviewers' comments. First, we reconsidered our methodological approach: given the small number of candidate genes (n = 2), the variable-selection advantages of LASSO could not be meaningfully realized. We therefore replaced the LASSO framework with standard logistic regression, which is more appropriate for this low-dimensional setting. Second, for the single-cell analysis, we have now provided detailed parameter information, including all relevant settings and thresholds used during data processing and analysis. Third, we have revised the manuscript language throughout to improve clarity and fluency.
